Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from InnoCare Pharma Ltd. ( (HK:9969) ).
InnoCare Pharma has scheduled a board meeting for 25 March 2026 to review and approve the annual results for the year ended 31 December 2025. The approval will pave the way for publication of the company’s full-year financial performance, a key milestone for investors tracking its operational progress and governance.
The announcement also reiterates the current composition of the board, led by Chairperson and executive director Dr. Jisong Cui alongside a mix of executive, non-executive and independent non-executive directors. The disclosure underscores the company’s adherence to corporate governance norms as it prepares to release audited results that will inform shareholders’ view on strategy and performance.
The most recent analyst rating on (HK:9969) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.
More about InnoCare Pharma Ltd.
InnoCare Pharma Limited is a Hong Kong-listed biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies. The company operates through subsidiaries and is overseen by a board comprising executive, non-executive and independent non-executive directors, reflecting a typical governance structure for a regional pharma issuer.
Average Trading Volume: 6,847,811
Technical Sentiment Signal: Hold
Current Market Cap: HK$17.67B
For a thorough assessment of 9969 stock, go to TipRanks’ Stock Analysis page.